|Day Low/High||19.00 / 19.89|
|52 Wk Low/High||12.90 / 28.35|
Celladon (CLDN) stock is soaring on heavy trading volume on Thursday, after the company announced a merger with the privately-held Eiger BioPharmaceuticals.
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Celladon Corporation (NASDAQ: CLDN) breached their fiduciary duties in connection with the proposed...
Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.
Beware of companies where 'insiders,' often top executives, are selling large blocks of stock. Here are five to closely monitor.
Glancy Prongay & Murray LLP ("GPM") announces the filing of a class action lawsuit on behalf of investors of Celladon Corporation ("Celladon" or the "Company") (NASDAQ:CLDN), who purchased shares between July 7,...
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Celladon Corporation ("Celladon") (NASDAQGM:CLDN) between July...
Try small stakes in several sector names to improve your odds. Also, don't trade after hours.
Goldberg Law PC ( www.Goldberglawpc.
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Celladon Corporation (NASDAQ: CLDN) common stock from July 7, 2014 through June 25, 2015, all dates inclusive, of the important August 31, 2015 lead...
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announced today that a securities fraud class action lawsuit has been filed in the U.
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation (NASDAQ:CLDN) common stock from July 7, 2014 through June 25, 2015, all...
Some biotech stocks way underperformed in this red-hot sector.
Celladon (CLDN) shares are falling more than 40% after the company announced that it's halting R&D as it prepares for a possible liquidation.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
These biotech stocks that trade for under $10 a share could be setting up to break out and trade higher soon.
I wanted to slam my forehead against the desk after the Avalanche CEO repeated for the 600th time, 'The key takeaway today is that it's a positive study.'
These under-$10 are making big moves higher today. Keep them on your breakout trading radar.